Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration

Geri A. Lake-Bakaar, Manreet K. Singh, Philip H. Kass, Leigh Griffiths

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD). Animals Eight client-owned small breed dogs (<15 kg) with CHF due to MMVD. Methods A prospective double-blind randomized placebo-controlled crossover study design was used. Data were recorded at baseline and 2 weeks post-administration of placebo or pimobendan. Average heart rate and incidence of arrhythmia were determined from 24 h Holter analysis. Owners completed a quality of life (QOL) questionnaire at each time point and recorded sleeping respiratory rates (SRR). Mixed effects analysis of variance, with dog as the random variable was used to compare values obtained between baseline, placebo, and pimobendan. Results Compared to baseline, QOL scores were significantly improved following administration of either placebo or pimobendan (p = 0.021 and p < 0.001, respectively). No significant differences in type or incidence of supraventricular or ventricular arrhythmia were identified. Average heart rate with pimobendan was significantly lower than baseline (p < 0.001). Compared to baseline, SRR was significantly lower with pimobendan (p = 0.004), and significantly different from placebo (p = 0.045). Conclusions No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia. The decrease in average heart rate and SRR may be reflective of superior heart failure control achieved with pimobendan therapy.

Original languageEnglish (US)
Pages (from-to)120-128
Number of pages9
JournalJournal of Veterinary Cardiology
Volume17
Issue number2
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

arrhythmia
dog breeds
Mitral Valve
placebos
Cardiac Arrhythmias
Dogs
Placebos
incidence
Incidence
heart failure
respiratory rate
Respiratory Rate
heart rate
Heart Failure
Heart Rate
quality of life
Cross-Over Studies
Quality of Life
Type 3 Cyclic Nucleotide Phosphodiesterases
Phosphodiesterase Inhibitors

Keywords

  • Canine
  • Congestive heart failure
  • Ventricular premature complex
  • Vetmedin

ASJC Scopus subject areas

  • veterinary(all)
  • Physiology
  • Medicine(all)

Cite this

Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. / Lake-Bakaar, Geri A.; Singh, Manreet K.; Kass, Philip H.; Griffiths, Leigh.

In: Journal of Veterinary Cardiology, Vol. 17, No. 2, 01.06.2015, p. 120-128.

Research output: Contribution to journalArticle

@article{a38b7c9d8fea46f69c230fe914af415a,
title = "Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration",
abstract = "Objective To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD). Animals Eight client-owned small breed dogs (<15 kg) with CHF due to MMVD. Methods A prospective double-blind randomized placebo-controlled crossover study design was used. Data were recorded at baseline and 2 weeks post-administration of placebo or pimobendan. Average heart rate and incidence of arrhythmia were determined from 24 h Holter analysis. Owners completed a quality of life (QOL) questionnaire at each time point and recorded sleeping respiratory rates (SRR). Mixed effects analysis of variance, with dog as the random variable was used to compare values obtained between baseline, placebo, and pimobendan. Results Compared to baseline, QOL scores were significantly improved following administration of either placebo or pimobendan (p = 0.021 and p < 0.001, respectively). No significant differences in type or incidence of supraventricular or ventricular arrhythmia were identified. Average heart rate with pimobendan was significantly lower than baseline (p < 0.001). Compared to baseline, SRR was significantly lower with pimobendan (p = 0.004), and significantly different from placebo (p = 0.045). Conclusions No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia. The decrease in average heart rate and SRR may be reflective of superior heart failure control achieved with pimobendan therapy.",
keywords = "Canine, Congestive heart failure, Ventricular premature complex, Vetmedin",
author = "Lake-Bakaar, {Geri A.} and Singh, {Manreet K.} and Kass, {Philip H.} and Leigh Griffiths",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jvc.2015.01.005",
language = "English (US)",
volume = "17",
pages = "120--128",
journal = "Journal of Veterinary Cardiology",
issn = "1760-2734",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration

AU - Lake-Bakaar, Geri A.

AU - Singh, Manreet K.

AU - Kass, Philip H.

AU - Griffiths, Leigh

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD). Animals Eight client-owned small breed dogs (<15 kg) with CHF due to MMVD. Methods A prospective double-blind randomized placebo-controlled crossover study design was used. Data were recorded at baseline and 2 weeks post-administration of placebo or pimobendan. Average heart rate and incidence of arrhythmia were determined from 24 h Holter analysis. Owners completed a quality of life (QOL) questionnaire at each time point and recorded sleeping respiratory rates (SRR). Mixed effects analysis of variance, with dog as the random variable was used to compare values obtained between baseline, placebo, and pimobendan. Results Compared to baseline, QOL scores were significantly improved following administration of either placebo or pimobendan (p = 0.021 and p < 0.001, respectively). No significant differences in type or incidence of supraventricular or ventricular arrhythmia were identified. Average heart rate with pimobendan was significantly lower than baseline (p < 0.001). Compared to baseline, SRR was significantly lower with pimobendan (p = 0.004), and significantly different from placebo (p = 0.045). Conclusions No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia. The decrease in average heart rate and SRR may be reflective of superior heart failure control achieved with pimobendan therapy.

AB - Objective To determine if pimobendan, a phosphodiesterase III inhibitor and calcium sensitizer with positive survival benefits, has an effect on incidence of arrhythmias compared to placebo in small breed dogs with congestive heart failure (CHF) due to myxomatous mitral valve degeneration (MMVD). Animals Eight client-owned small breed dogs (<15 kg) with CHF due to MMVD. Methods A prospective double-blind randomized placebo-controlled crossover study design was used. Data were recorded at baseline and 2 weeks post-administration of placebo or pimobendan. Average heart rate and incidence of arrhythmia were determined from 24 h Holter analysis. Owners completed a quality of life (QOL) questionnaire at each time point and recorded sleeping respiratory rates (SRR). Mixed effects analysis of variance, with dog as the random variable was used to compare values obtained between baseline, placebo, and pimobendan. Results Compared to baseline, QOL scores were significantly improved following administration of either placebo or pimobendan (p = 0.021 and p < 0.001, respectively). No significant differences in type or incidence of supraventricular or ventricular arrhythmia were identified. Average heart rate with pimobendan was significantly lower than baseline (p < 0.001). Compared to baseline, SRR was significantly lower with pimobendan (p = 0.004), and significantly different from placebo (p = 0.045). Conclusions No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia. The decrease in average heart rate and SRR may be reflective of superior heart failure control achieved with pimobendan therapy.

KW - Canine

KW - Congestive heart failure

KW - Ventricular premature complex

KW - Vetmedin

UR - http://www.scopus.com/inward/record.url?scp=84931008698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931008698&partnerID=8YFLogxK

U2 - 10.1016/j.jvc.2015.01.005

DO - 10.1016/j.jvc.2015.01.005

M3 - Article

C2 - 26007710

AN - SCOPUS:84931008698

VL - 17

SP - 120

EP - 128

JO - Journal of Veterinary Cardiology

JF - Journal of Veterinary Cardiology

SN - 1760-2734

IS - 2

ER -